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doi:10.1016/j.jmii.2011.11.001Background/Purpose: Peanut allergy is very common in Western countries, although it is
seldom encountered in Eastern countries. Peanuts are comprised of at least 11 components,
but the contribution to clinical symptoms by each component in each individual is not known.
This study investigated the distributions of sensitivity to peanut allergen components among
Taiwanese children who were sensitized to peanuts and followed the evolution of sensitization
patterns to these components.
Methods: We enrolled 29 preschool children (ageZ 2.11 1.36 years) who were sensitized to
peanuts above class 3. Serum was analyzed for specific immunoglobulin E (IgE) antibodies to
recombinant Ara h 1, Ara h 2, Ara h 3, Ara h 8, and Ara h 9. Allergen component-specific IgE
0.35 kUA/L was defined as positive. Eighteen children were retested 22.64  5.1 months
later. Peanut allergy symptoms were recorded from detailed questionnaires.
Results: The percentages of children sensitized to Ara h 1, 2, 3, 8, and 9 were, respectively,
51.8%, 65.5%, 62.1%, 13.8%, and 24.1%. Regarding changing patterns of peanut component
sensitization at follow-up, children with clinical symptoms to peanuts had persistent eleva-
tions of Ara h 2-specific IgE: 12.6  1.01 up to 34.15  19.4 kUA/L; pZ 0.144. In contrast,
Ara h 2 concentrations decreased significantly in children without clinical symptoms. Ara h 8
and 9 were nonspecific for children with or without symptoms.
Conclusion: Ara h 1, Ara h 2, and Ara h 3 were major components contributing to peanut sensi-
tization in Taiwanese children. Ara h 2 was probably the most important component that
contributed to clinical symptoms and remained steady in children who had peanut allergy.
Copyright ª 2011, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Allergy, Asthma and Rheumatology, Department of Pediatrics, Chang Gung Memorial Hospital, 5,
.org.tw (K.-W. Yeh).
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Peanut allergies in Taiwanese preschool children 91Introduction countries often have LTP allergy due to the high consump-Allergy to peanuts is one of the leading causes of fatal
allergic reactions. The prevalence of peanut allergy has
increased dramatically in the last decade. It currently
affects about 1.15%e1.5% of these populations, and there is
an estimated threefold increase in reported peanut allergies
among Westernized countries.1e4 However, peanut allergy
is not common in Asia, and its reported prevalence is about
0.4%e0.6%.5 Children with allergies to milk or egg whites
usually develop tolerance and become asymptomatic as
they grow older. In contrast, peanut allergy symptoms are
usually lifelong, but a minority of patients may outgrow the
reactions over time.6 Consuming peanut-containing prod-
ucts can lead to shock and even death among those with
severe peanut allergies.7,8 Therefore, it is very important to
diagnose peanut allergy at an early stage.
The current clinical gold standard for diagnosing peanut
allergy is an oral food challenge test (OFC),9 but it is time-
consuming, expensive, and extremely risky in clinical
practice.10 Therefore, a skin prick test or testing for serum
levels of peanut-specific immunoglobulin E (IgE) are
currently used as replacements in the clinic.11,12 However,
people who are positive by peanut-specific IgE tests can only
be classified as having a peanut sensitization.13 Evidence is
required from a patient’s clinical history of peanut contact
experience for a diagnosis of peanut allergy. It has also been
reported that only a skin prick result larger than 8 mm or
a peanut-specific IgE level higher than 15 kUA/L had a high
predictive value for clinical peanut allergy.14
A possible reason for the ambiguity between peanut
sensitization and peanut allergy is that the allergens used in
test kits are derived from crude peanut protein extracts,
which contain both allergenic and nonallergenic molecules.
In addition, some of these molecules may cross-react with
pollens or other allergens in foods.15,16 Overall, this leads
to discrepancies in test results and clinical diagnoses.
At least 11 different allergen components have been
found to be associated with peanut allergy. These are
designated Ara h 1-11 (Arachis hypogaea). Among these, Ara
h 1, Ara h 2, and Ara h 3 are the major peanut allergen
components based on their protein ratios and cellular
activities. These are seed storage proteins comprised of
vicilin, conglutin, and glycinin, respectively.17 It was
reported that American patients who became allergic
around 1 year of age presented more frequently with IgE
antibodies to rAra h 1 to 3 (56.7%e90.0%) than Swedish
patients (37.1%e74.3%), followed by Spanish patients (16%e
42%).18 Ara h 4 and Ara h 3 are nearly identical isoforms,19
and, additionally, Ara h 5 and Ara h 8 are both related to
pollen allergy and are not seed storage proteins. Ara h 5 is
a profilin protein in peanuts, which presents low quantity in
peanuts and leads to a cross-reaction with Bet v 2, the birch
pollen profilin20 and Ara h 6 and Ara h 7 are proteins
homologous to Ara h 2.21 Ara h 8, a homologous protein of
Bet v 1, the major allergen in birch pollen, is heat sensitive
and labile to digestion, and usually results in clinical
symptoms associated with oral allergy syndrome.22 Ara h 9 is
a nonspecific lipid-transfer protein (LTP), with properties of
heat and acid resistance. Its clinical symptoms include
systemic allergy and oral allergy. People in Mediterraneantion of vegetables and fruits, among which Ara h 9 is the
major causative allergen and is more relevant than Ara h
1-3.23 Ara h 10 and Ara h 11 are both plant protein oleosins
that were obtained from oil bodies from peanut and were
not realized until their clinical relevance was present.
Peanut allergy has different clinical and immunologic
patterns in different areas of the world. We investigated
whether the uncommon presentation of peanut allergy in
Taiwanese preschool children could be related to a different
sensitization pattern to peanut allergen components.
Methods
Study population
From April 2007 to April 2009, 3936 children with allergic
diseases had been tested for serum levels of peanut-specific
IgE in the Pediatric Allergy and Asthma Center of Chang-Gung
Memorial Hospital. Among these children, 215 were tested as
positive (peanut-specific IgE levels 0.35 kUA/L). There
were only 29 preschoolers (age between 6 months to 6 years)
out of 215 test-positive children who met our criteria by
having peanut-specific IgE levels higher than 3.5 kUA/L (or
ImmunoCAP above class 3); then, their blood samples were
tested for peanut component-specific IgE. After 1.5 to 2
years, they returned for follow-up blood tests for peanut
component-specific IgE and parents completed a question-
naire about the child’s allergic symptoms. The questionnaire
included items such as the patient’s consumption of peanut-
containing products during the follow-up period. If peanut
exposure was confirmed, we specifically inquired about the
occurrence of allergic symptoms, including skin rash, eyelid
swelling, cough, mouth numbness, heart palpitations, and
difficulty breathing when the child consumed peanut-
containing products. Written informed consent were
obtained from the main caregiver for all study patients.
Determination of sensitization
Serum was analyzed for specific IgE antibodies to peanut-
recombinant Ara h 1, Ara h 2, Ara h 3, Ara h 8, and Ara h 9 by
ImmunoCAP (Phadia, Sweden). An allergen-specific IgE level
0.35 kUA/L was defined as positive. Levels between 0.35
and 100 kUA/L were recorded.
Statistics
A Wilcoxon Signed Rank Test was used to compare changes
of specific IgE levels with peanut allergen components




The average age of the 29 children with peanut sensitiza-
tion was 2.11 1.36 years (range: 0.53e5.7 years), and all
Table 1 Positive rates to peanut allergen components
(total nZ 29)










6þ 0 1 (3.5) 0 0 0
5þ 0 0 0 0 0
4þ 1 (3.5) 4 (13.8) 1 (3.5) 0 0
3þ 7 (24.1) 5 (17.3) 4 (13.8) 1 (3.5) 2 (6.8)
2þ 6 (20.7) 7 (24.1) 10 (34.5) 1 (3.5) 4 (13.8)
1þ 1 (3.5) 2 (6.8) 3 (10.3) 2 (6.8) 1 (3.5)
0 14 (48.2) 10 (34.5) 11 (37.9) 25 (86.2) 22 (75.9)
1þ 15 (51.8) 19 (65.5) 18 (62.1) 4 (13.8) 7 (24.1)
Reference ranges for Allergen IgE tests: Class 0 is < 0.35 kUA/L
or absent; Class 1 is  0.35 kUA/L but < 0.7 kUA/L; Class 2 is
 0.7 kUA/L but < 3.5 kUA/L; Class 3 is  3.5 kUA/L but
< 17.5 kUA/L; Class 4 is  17.5 kUA/L but < 50 kUA/L; Class 5 is
 50 kUA/L but < 100 kUA/L; Class 6 is  100 kUA/L.
92 Y.-T. Lin et al.of them were also sensitized to egg white; 23 were sensi-
tized to milk, 12 were sensitized to shrimps and crabs, and
nine were sensitized to cod. Their clinical histories showed
that 26 children also suffered from allergic rhinitis, 25
children had atopic dermatitis, and 15 children had asthma
(data not shown). Results for serum concentrations of
peanut allergen component-specific IgE for these 29 chil-
dren were: 15.24 2.02 kUA/L for peanut, 3.17 5.64 for
Ara h 1, 8.96 2.02 for Ara h 2, 2.74 6.14 for Ara h 3,
0.44 1.48 for Ara h 8, and 1.24 3.68 for Ara h 9 (Fig. 1).
As shown in Table 1, among these 29 children who were
positive for peanut sensitization, the percentages that also
tested positive for peanut allergen components were:
51.8% for Ara h 1, 65.5% for Ara h 2, 62.1% for Ara h 3, 13.8%
for Ara h 8, and 24.1% for Ara h 9.
Follow-up results
Eighteen of the 29 children (16 boys and two girls) had
follow-up serum tests for peanut allergen component-
specific antibodies. Their average age was 2.27 1.39
years when they first had peanut allergen tests, and their
average age at follow-up tests was 4.15 1.44 years old.
After a mean interval of 22.64 5.1 months, the serum
level of IgE against peanut changed from 8.42 8.00 kUA/L
to 7.84 15.49 kUA/L (pZ 0.094), and the positive rate for
peanut sensitization declined from 100% to 77.8% (data not
shown).
Ara h 1-specific IgE levels declined from 2.59 4.75 kUA/
L to 1.89 5.59 kUA/L (pZ 0.043), and the positive rate
decreased from 44.4% to 33.3% (data not shown). Ara h 2-
specific IgE levels increased from 3.37 6.68 kUA/L to
7.83 16.62 kUA/L (pZ 0.523), while the positive rate
decreased from 55.6% to 38.9% (data not shown). Ara h
3 specific-IgE levels changed from 1.50 1.74 kUA/L to
0.56 1.26 kUA/L (pZ 0.02), and the positive rate declined
from 61.1% to 22.2% (data not shown). IgE levels against Ara
h 8, a pollen allergy-related allergen, and Ara h 9, theFigure 1. IgE levels of peanut allergen components in all
peanut-sensitized children. Serum concentrations of IgE
against recombinant Ara h 1, Ara h 2, Ara h 3, Ara h 8, and Ara h
9 in 29 children allergic to peanuts. Horizontal lines indicate
mean values.major peanut allergen in the Mediterranean region,
decreased from 0.20 0.41 kUA/L and 0.24 0.36 kUA/L
to 0.08 0.09 kUA/L (pZ 0.023) and 0.06 0.05 kUA/L
(pZ 0.001), respectively. The positive rates to these
components declined to 0% from 11.1% and 16.7% (data not
shown), respectively (Fig. 2).
Questionnaires were given to the parents of these 18
children who were sensitive to peanuts to investigate
whether they had consumed peanut-containing products
during the follow-up period. If positive exposure history
was confirmed, we further inquired about the occurrence
of the associated allergic symptoms. Four children had
shown allergic symptoms, such as a rash, eyelid swelling,
cough, or itching over the body, while the other 14 children
showed no allergic symptoms (seven children consumed
peanut-containing products while the other seven children
avoided peanut-containing products). The first and the
follow-up values of peanut allergen component specific IgE
in these two groups of children were compared.
In the group of children with allergic symptoms (nZ 4),
although serum IgE levels against these peanut allergen
components changed at the follow-up tests, they did not
show statistically significant differences. For these children,
serum IgE levels against peanut allergen changed from
13.88 10.75 kUA/L to 27.98 25.15 kUA/L (pZ 0.465).
The detailed results were shown in Table 2.
By contrast, for these asymptomatic children (nZ 14),
overall the concentrations of IgE against peanut components
decreased significantly and the positive rate also decreased.
For these children, serum IgE levels against peanut allergen
declined from 6.85 6.72 kUA/L to 2.09 2.69 kUA/L (pZ
0.001); serum IgE levels against Ara h 1 declined from
1.44 3.03 kUA/L to 0.47 1.04 kUA/L (pZ 0.002); serum
IgE against Ara h 2 decreased from 0.73 0.88 kUA/L to
0.31 0.57 kUA/L (pZ 0.033); and serum IgE against Ara h 3
decreased from 1.37 1.58 kUA/L to 0.29 0.40 kUA/L
[pZ 0.001 (Table 2)].
We further divided the asymptomatic group (nZ 14)
into two subgroups: peanut-avoiding and tolerant group.
In the tolerant subgroup (nZ 7), the levels of IgE against
peanut components decreased significantly. However, in
Figure 2. Changes of IgE levels. Serum specific IgE levels to (A) crude peanut; (B) rAra h 1, (C) rAra h 2; and (D) rAra h 3 were
determined for 18 peanut-sensitized children at baseline and at an average of 22 months later. A Wilcoxon Signed Rank Test was
used to compare changes of IgE levels to peanut allergen components between two time points, and a p value <0.05 was
considered statistically significant.
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against peanut components also decreased significantly,
except those of Ara h 2 and Ara h 8 (Table 3).Discussion
The prevalence of peanut allergy in Western countries has
been increasing in recent years and is usually accompanied
by severe allergic reactions that may lead to death.
Therefore, most of the studies on peanut allergy are from
Europe and North America.18 By contrast, the prevalence
and mortality rate due to peanut allergy in Asia are rela-
tively low and have been less investigated in the literature.Table 2 Baseline and follow-up serum specific IgE levels
Reported symptoms to peanut Yes (NZ4)
sensitization 1st 2nd
n IgE(kUA/L) n IgE
peanut 4 13.88 10.75 4 27.98
rAra h 1 3 6.60 7.78 3 6.85 1
rAra h 2 3 12.6 1.01 4 34.15
rAra h 3 2 1.96 2.43 1 1.51 2
rAra h 8 2 0.60 0.80 0 0.18 0
rAra h 9 2 0.50 0.61 0 0.08 0
“n” means numbers of patients positive for testing peanut componen
P-value was derived from Wilcoxon Signed Rank Tests, and p-value <Even children who live in Asia but who were born in Western
countries were at a higher risk of peanut and tree nut
allergy compared with those born in Asia.5 Our study
showed that in children with allergic diseases in Taiwan,
the incidence of peanut sensitization was low, and the
number with a genuine peanut allergy was even lower.
The Ara h 1, 2 and 3, which are the major components of
peanut allergy, play an important role in symptomatic
patients in Western countries.24 Chiang and colleagues25
investigated peanut allergen component distributions in
Singapore. Their results indicated that the positive rates to
native Ara h 1, native Ara h 2, and recombinant Ara h 3 in
children who were hypersensitive to peanuts were 87.1%,
87.1%, and 54.8%, respectively, suggesting that Ara h 1-3No (NZ14)
P 1st 2nd P
n IgE n IgE
25.15 0.465 14 6.85 6.72 10 2.09 2.69 0.001
1.41 0.715 5 1.44 3.03 3 0.47 1.04 0.002
19.4 0.144 7 0.73 0.88 3 0.31 0.57 0.033
.59 1.000 9 1.37 1.58 3 0.29 0.40 0.001
.13 0.273 0 0.09 0.07 0 0.05 0.04 0.022
.06 0.273 1 0.17 0.24 0 0.05 0.05 0.002
t allergens.
0.05 was considered significant.
Table 3 Changes of IgE levels in the asymptomatic group
sensitization peanut-tolerant subgroup (NZ7) peanut-avoiding subgroup (NZ7)
1st 2nd P 1st 2nd P
n IgE(kUA/L) n IgE n IgE n IgE
peanut 7 5.39 2.80 4 1.21 1.24 0.018 7 8.32 9.22 6 2.97 3.51 0.018
rAra h 1 2 1.68 3.85 1 0.58 1.42 0.018 3 1.21 2.23 2 0.36 0.56 0.043
rAra h 2 3 0.50 0.46 0 0.09 0.04 0.028 4 0.96 1.16 3 0.53 0.76 0.398
rAra h 3 4 0.83 0.92 1 0.19 0.33 0.028 5 1.90 1.98 2 0.39 0.47 0.018
rAra h 8 0 0.09 0.05 0 0.05 0.05 0.017 0 0.09 0.09 0 0.05 0.04 0.225
rAra h 9 1 0.22 0.32 0 0.05 0.05 0.028 0 0.12 0.11 0 0.05 0.06 0.028
“n” means numbers of patients positive for testing peanut component allergens.
P-value was derived from Wilcoxon Signed Rank Tests, and p-value <0.05 was considered significant.
94 Y.-T. Lin et al.was also a major allergen for Asian peanut-sensitized chil-
dren.25 After examining the major allergen components
that caused peanut sensitization in preschool children, we
found that the major contributing peanut allergen compo-
nents in Taiwan were also Ara h 1-3, although the sensitivity
rate to each component was lower. Of these three
components, the levels of IgE against Ara h 2 were the
highest, followed by Ara h 1 and Ara h 3. In a previous study,
Ara h 2 was considered to be the most important compo-
nent because the threshold for inducing basophil-
degranulation and histamine release for Ara h 2 was lower
than that of Ara h 1 and Ara h 3, which may be associated
with the ability of peanut allergen components to induce
basophil degranulation and histamine release.26
Moreover, we compared the positive rates with Ara h 9,
the major peanut allergen in the Mediterranean area, and
Ara h 8, a pollen allergy-associated allergen. Our study
showed that the positive rates to Ara h 8 and Ara h 9 were
only 13.8% and 24.1 %, respectively, and the avidity only
had an epitope valence of 1 to 3. However, a study showed
that the prevalence of pollen allergy was less than 2% in
a population of primary schoolechildren aged 7e8 years in
Taiwan.27 This indicated that the proportion of children
with pollen allergy was very low in Taiwan, and our results
suggested that the proportion caused by cross-reactivity of
a pollen allergen and peanut allergen was also very low.
Although 45.2% of the Mediterranean population that is
allergic to peanuts is hypersensitive to Ara h 9, our inves-
tigation indicated that Ara h 9 was not a major allergen
causing peanut sensitization in Taiwan. It is possible that
the children in our study were too young to have been
exposed to a variety of foods, which could have minimized
the possibility of peanut allergy caused by cross-reactions
with LTP in other foods.
It has been reported that peanut allergy lingers
throughout life.6 Therefore, we kept track of the peanut-
sensitized children to see if their peanut sensitization was
ameliorated as these children grew older. Our result
showed that both crude peanut and Ara h 2 specific IgE had
no statistical difference between initial and the follow-up
test results. This indicated that the progression of peanut
sensitization did not vary with age, which was attributed to
Ara h 2 instead of other components. Furthermore, our
questionnaire results indicated that there were four chil-
dren consuming peanut-containing products who developedallergic symptoms. Their Ara h 2 level remained steady
year apart, and it indicated that Ara h 2 was probably
associated with peanut-induced allergy in Taiwanese chil-
dren. Furthermore, in our asymptomatic group, the levels of
peanut-specific or peanut allergen components-specific IgE
were both decreased and statistically significant at 2-year
follow-ups, which suggested that serum peanut allergen
components-specific IgE gradually diminished if no symp-
toms occurred. Analysis of peanut-avoiding and tolerant
subgroups also showed that the titer of Ara h 2 specific IgE
decreased slower than other specific IgE in peanut-avoiding
subgroup, implying that Ara h 2 IgE is relatively more stable
compared with those of other allergen components. Inter-
estingly, Ara h 2 levels and the positive rate of sensitization
were lower in the group without allergy than in the group
with allergy at the initial test results. This could be related
to the cut-off value for peanut- or Ara h 2-specific IgE. If we
set the peanut specific IgE level at 15 kUA/L, we had a higher
predictive value for clinical peanut allergy.14
According to a study by Asarnolj and others,28 97% of
children 8 years of age who were hypersensitive to both Ara
h 2 and Ara h 1 or Ara h 3 developed more severe allergic
symptoms than children who were only hypersensitive to
Ara h 2. In our study, we found that in the allergic group,
the levels of sIgE against peanut and Ara h 2 were increased
and the positive rate was 100%. There were also three
children with sensitized Ara h 2 who had concomitant IgE
reactivity to Ara h 1 or Ara h 3. By contrast, the levels of
sIgE against Ara h 8 and Ara h 9 decreased to be unre-
markable after follow-up in the allergic children.
This study revealevd that the levels of serum sIgE
against Ara h 1, 2, and 3 either remained constant or
increased in Taiwanese children who were allergic to
peanuts. Based on the positive rates and serum levels, we
found that Ara h 2 was the major contributing allergen,
which was similar to results by Flinterman and others in
2007.29 They showed that the Ara h 2 IgE expression level
was higher than those of Ara h 1 and Ara h 3 in peanut-
allergic children by IgE immunoblotting. They also
showed that 20 months after food stimulation Ara h 1-3 IgE
levels remained unchanged. However, that study investi-
gated positive rates, while our study further analyzed
variation on IgE levels. In addition, our study suggested
that Ara h 8 and Ara h 9 may not be associated with peanut
allergy in Taiwan.
Peanut allergies in Taiwanese preschool children 95In conclusion, Ara h 1, Ara h 2, and Ara h 3 were found to
be major components of peanut sensitization in children in
Taiwan. Ara h 2 was probably the most important compo-
nent that contributed to clinical symptoms and remained at
steady levels in children who were allergic to peanuts.References
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